Patents by Inventor Dan T. Stinchcomb

Dan T. Stinchcomb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6518266
    Abstract: The present invention is directed to novel pyrazole derivatives and their use as pesticidal agents. The pyrazole derivatives have Formula I: or a salt thereof, where R1 represents R5O, R5SO2, R5SO or R5S in which R5 is as defined herein; X is halo, cyano, C1-6 alkoxycarbonyl, C2-6 alkynyl, optionally substituted C6-14 aryl or an optionally substituted 5- to 7-membered heteroaromatic ring linked to thiazole via a carbon-carbon bond; R2 is hydrogen, amino, chloro, bromo, iodo, cyano, C1-6 alkoxy, C1-6 alkyl or C6-10 aryl; and R3-R7 each represent hydrogen, halogen, straight- or branched-chain C1-4 alkyl or C1-4 alkoxy, either of which is unsubstituted or substituted by one or more halogen atoms, straight- or branched-chain C1-4 alkylthio or C1-4 alkylsulphinyl, either of which is substituted by one or more halogen atoms, nitro, cyano, or straight- or branched-chain C1-4 alkylsulphonyl group which is unsubstituted or substituted by one or more halogen atoms.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: February 11, 2003
    Assignees: 3-Dimensional Pharmaceuticals, Heska Corporation
    Inventors: Daljit S. Dhanoa, Dario Doller, Sanath Meegalla, Richard M. Soll, Nancy Wisnewski, Gary Silver, Dan T. Stinchcomb, R. Lee Seward, Dimitris Agrafiotis, Deyou Sha
  • Patent number: 6506784
    Abstract: The present invention is directed to inhibiting pest GABA receptors by contacting said receptors with a compound of Formula I: The invention is also directed to methods of controlling pests, especially insects and arachnids such as fleas and ticks, and to novel compounds within the scope of Formula I.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: January 14, 2003
    Assignees: 3-Dimensional Pharmaceuticals, Inc., Heska Corporation
    Inventors: Daljit S. Dhanoa, Dario Doller, Sanath Meegalla, Richard M. Soll, Dimitris Agrafiotis, Nancy Wisnewski, Gary M. Silver, Dan T. Stinchcomb, R. Lee Seward
  • Publication number: 20030003469
    Abstract: Enzymatic RNA molecules which cleave rel A mRNA.
    Type: Application
    Filed: January 23, 2002
    Publication date: January 2, 2003
    Applicant: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Kenneth G. Draper, James McSwiggen
  • Publication number: 20020177568
    Abstract: The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, allozymes and antisense, which modulate the expression or function of NFKB genes, such as REL-A, REL-B, REL (c-rel), NFKB1 (p105/p50) and NFKB2 (p100)/p52/p49).
    Type: Application
    Filed: May 23, 2001
    Publication date: November 28, 2002
    Inventors: Dan T. Stinchcomb, James McSwiggen, Kenneth G. Draper
  • Patent number: 6436644
    Abstract: The present invention relates to enzymatic RNA molecules which cleave ICAM-1 mRNA.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: August 20, 2002
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Susan Grimm, Dan T. Stinchcomb, James McSwiggen, Sean Sullivan, Kenneth G. Draper
  • Patent number: 6410224
    Abstract: Enzymatic RNA molecules which cleave rel A mRNA.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: June 25, 2002
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Kenneth G. Draper, James McSwiggen
  • Patent number: 6194150
    Abstract: Nucleic acid molecule which blocks synthesis and/or expression of an mRNA encoding B7-1, B7-2, B7-3 and/or CD40.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: February 27, 2001
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Thale Jarvis, James McSwiggen
  • Patent number: 6159692
    Abstract: An enzymatic nucleic acid molecule which cleaves an immunodeficiency virus RNA in a gene required for viral replication, e.g., the nef or tat gene regions.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: December 12, 2000
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Kenneth G. Draper, Bharat Chowrira, James McSwiggen, Dan T. Stinchcomb, James D. Thompson
  • Patent number: 6132967
    Abstract: Enzymatic RNA molecules which cleave ICAM-1 mRNA.
    Type: Grant
    Filed: May 1, 1998
    Date of Patent: October 17, 2000
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Susan Grimm, Dan T. Stinchcomb, James McSwiggen, Sean Sullivan, Kenneth G. Draper
  • Patent number: 6106841
    Abstract: The present invention relates to a novel method to immunize an animal against a heterologous antigen. The method includes the step of administering to the animal, by an intranasal route, a conjunctival route, or a combination thereof, a composition comprising a recombinant raccoon poxvirus having a nucleic acid molecule encoding such a heterologous antigen. Animals to be immunized include those that are susceptible to such routes of recombinant raccoon poxvirus administration. Preferred animals to immunize include felids. Preferably, any immune response generated by the animal against viral antigens of the recombinant raccoon poxvirus is sufficiently small so as to not prevent the animal from eliciting an immune response to a heterologous antigen encoded by a recombinant raccoon poxvirus subsequently administered to the animal.
    Type: Grant
    Filed: February 4, 1998
    Date of Patent: August 22, 2000
    Assignee: Heska Corporation
    Inventors: Jorge E. Osorio, Dan T. Stinchcomb
  • Patent number: 6103890
    Abstract: Enzymatic nucleic acid molecules which cleave c-fos RNA.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: August 15, 2000
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Thale Jarvis, James A. McSwiggen, Dan T. Stinchcomb
  • Patent number: 5972704
    Abstract: An enzymatic nucleic acid molecule which cleaves an immunodeficiency virus RNA in a gene required for viral replication, e.g., the nef or tat gene regions.
    Type: Grant
    Filed: August 13, 1997
    Date of Patent: October 26, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Kenneth G. Draper, Bharat Chowrira, James McSwiggen, Dan T. Stinchcomb, James D. Thompson
  • Patent number: 5877022
    Abstract: Enzymatic RNA molecules which cleave apo(a) mRNA.
    Type: Grant
    Filed: December 26, 1996
    Date of Patent: March 2, 1999
    Assignees: Ribozyme Pharmaceuticals, Inc, Warner Lambert
    Inventors: Dan T. Stinchcomb, James McSwiggen, Roger S. Newton, Randy Ramharack
  • Patent number: 5877021
    Abstract: Nucleic acid molecule which blocks synthesis and/or expression of an mRNA encoding B7-1.
    Type: Grant
    Filed: January 12, 1996
    Date of Patent: March 2, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Thale Jarvis, James McSwiggen
  • Patent number: 5837542
    Abstract: Enzymatic RNA molecules which cleave ICAM-1 mRNA.
    Type: Grant
    Filed: August 17, 1994
    Date of Patent: November 17, 1998
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Susan Grimm, Dan T. Stinchcomb, James McSwiggen, Sean Sullivan, Kenneth G. Draper
  • Patent number: 5817796
    Abstract: Enzymatic nucleic acid molecules which cleave c-myb RNA or other RNAs associated with restenosis or cancer.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: October 6, 1998
    Inventors: Dan T. Stinchcomb, Kenneth Draper, James McSwiggen, Thale Jarvis
  • Patent number: 5811300
    Abstract: Enzymatic RNA molecules which cleave TNF-.alpha. mRNA.
    Type: Grant
    Filed: September 23, 1994
    Date of Patent: September 22, 1998
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Sean Sullivan, Kenneth Draper, Kevin Kisich, Dan T. Stinchcomb, James McSwiggen
  • Patent number: 5807743
    Abstract: A nucleic acid molecule which blocks synthesis and/or expression of an IL-2R encoded RNA, wherein said nucleic acid molecule is used to treat graft rejection, an autoimmune disease, cancer, psoriasis, an allergy or other inflammatory disease.
    Type: Grant
    Filed: December 3, 1996
    Date of Patent: September 15, 1998
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, James A. McSwiggen
  • Patent number: 5731295
    Abstract: An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of an arthritic condition.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: March 24, 1998
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Kenneth G. Draper, Pamela Pavco, James McSwiggen, John Gustofson, Dan T. Stinchcomb
  • Patent number: 5693535
    Abstract: An enzymatic nucleic acid molecule which cleaves an immunodeficiency virus RNA in a gene required for viral replication, e.g., the nef or tat gene regions.
    Type: Grant
    Filed: July 7, 1994
    Date of Patent: December 2, 1997
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Kenneth G. Draper, Bharat Chowrira, James McSwiggen, Dan T. Stinchcomb, James D. Thompson